Yosef Shamay

Title: Yosef Shamay: Innovator in Cancer Therapy

Introduction

Yosef Shamay is a notable inventor based in Zichron Yaakov, Israel. He has made significant contributions to the field of cancer therapy through his innovative research and development of targeted drug delivery systems.

Latest Patents

Yosef Shamay holds a patent for "PI3K inhibitors and uses thereof." This patent represents a significant advance in cancer therapy by developing a new, targeted drug delivery paradigm coupled with improved PI3K inhibitors, specifically PI3Kα inhibitors. The patent includes compounds such as those of Formula (I) and (II), along with their pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs. These compounds are useful for the treatment and prevention of various diseases, particularly proliferative diseases like cancer. Additionally, the patent describes nanoparticles and nanogels, such as P-selectin targeting nanoparticles, that encapsulate these compounds for targeted delivery to cancer cells or tumors.

Career Highlights

Throughout his career, Yosef Shamay has worked with prestigious institutions, including the Sloan Kettering Institute for Cancer Research and the Tri-Institutional Therapeutics Discovery Institute. His work has focused on advancing cancer treatment methodologies and improving patient outcomes through innovative drug delivery systems.

Collaborations

Yosef has collaborated with notable colleagues in his field, including Makoto Fushimi and Maurizio Scaltriti. These collaborations have further enhanced his research and contributed to the development of effective cancer therapies.

Conclusion

Yosef Shamay's contributions to cancer therapy through his innovative patent on PI3K inhibitors highlight his role as a significant inventor in the medical field. His work continues to pave the way for advancements in targeted drug delivery systems, ultimately benefiting patients worldwide.